Clinical and Experimental Reproductive Medicine

The Korean Society for Reproductive Medicine (대한생식의학회)
권호 표지
DOI QR코드

DOI QR Code

The effect of methyltestosterone on in vitro fertilization outcomes: A randomized clinical trial on patients with low ovarian response

  • Venus Haj Aliakbar (Department of Obstetrics and Gynecology, Arash Women's Hospital, Tehran University of Medical Sciences) ;
  • Fatemeh Davari Tanha (Department of Obstetrics and Gynecology, Yas Hospital, Tehran University of Medical Sciences) ;
  • Firouzeh Akbari Asbagh (Department of Obstetrics and Gynecology, Yas Hospital, Tehran University of Medical Sciences) ;
  • Mahbod Ebrahimi (Department of Obstetrics and Gynecology, Yas Hospital, Tehran University of Medical Sciences) ;
  • Zahra Shahraki (Department of Obstetrics and Gynecology, Amir-Al-Momenin Hospital, Zabol University of Medical Sciences)
  • Received : 2023.02.07
  • Accepted : 2023.11.27
  • Published : 2024.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: The aim of this study was to compare the outcomes of in vitro fertilization (IVF) in patients with a poor ovarian response who used methyltestosterone, versus those using a placebo, in an infertility clinic setting. Methods: This clinical trial included 120 women who had undergone IVF with intracytoplasmic sperm injection due to poor ovarian reserve and infertility. The study took place at the Yas Infertility Center in Tehran, Iran, between January 1, 2018 and January 1, 2019. In the intervention group, 25 mg of methyltestosterone was administered daily for 2 months prior to the initiation of assisted reproductive treatment. The control group was given placebo tablets for the same duration before starting their cycle. Each group was randomly assigned 60 patients. All analyses were performed using SPSS ver. 23 (IBM Corp.). Results: The endometrial thickness in the intervention group was 7.57±1.22 mm, whereas in the control group, it was 7.11±1.02 (p=0.028). The gonadotropin number was significantly higher in the control group (64.7±13.48 vs. 57.9±9.25, p=0.001). However, there was no significant difference between the two groups in the antral follicular count. The chemical and clinical pregnancy rates in the intervention group were 18.33% and 15% respectively, compared to 8.33% and 6.67% in the control group. The rate of definitive pregnancy was marginally higher in the intervention group (13.3% vs. 3.3%, p=0.05). Conclusion: The findings of this study suggest that pretreatment with methyltestosterone significantly increases endometrium thickness and is associated with an increase in the definitive pregnancy rate.

Keywords

Acknowledgement

We gratefully acknowledge the kind support of the participants for their invaluable collaboration in this study, as well as the staff of Yas Hospital.

References

  1. Vollenhoven B, Osianlis T, Catt J. Is there an ideal stimulation regimen for IVF for poor responders and does it change with age? J Assist Reprod Genet 2008;25:523-9.
  2. Tarlatzis BC, Zepiridis L, Grimbizis G, Bontis J. Clinical management of low ovarian response to stimulation for IVF: a systematic review. Hum Reprod Update 2003;9:61-76.
  3. Barad D, Brill H, Gleicher N. Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. J Assist Reprod Genet 2007;24:629-34.
  4. Burger HG. Androgen production in women. Fertil Steril 2002;77 Suppl 4:S3-5.
  5. Bosdou JK, Venetis CA, Kolibianakis EM, Toulis KA, Goulis DG, Zepiridis L, et al. The use of androgens or androgen-modulating agents in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis. Hum Reprod Update 2012;18:127-45.
  6. Gonzalez-Comadran M, Duran M, Sola I, Fabregues F, Carreras R, Checa MA. Effects of transdermal testosterone in poor responders undergoing IVF: systematic review and meta-analysis. Reprod Biomed Online 2012;25:450-9.
  7. Vendola KA, Zhou J, Adesanya OO, Weil SJ, Bondy CA. Androgens stimulate early stages of follicular growth in the primate ovary. J Clin Invest 1998;101:2622-9.
  8. Kara M, Aydin T, Aran T, Turktekin N, Ozdemir B. Does dehydroepiandrosterone supplementation really affect IVF-ICSI outcome in women with poor ovarian reserve? Eur J Obstet Gynecol Reprod Biol 2014;173:63-5.
  9. Barad D, Gleicher N. Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Hum Reprod 2006;21:2845-9.
  10. Dean AG, Sullivan KM, Soe MM. OpenEpi: open source epidemiologic statistics for public health [Internet]. OpenEpi; 2011 [cited 2023 Dec 8]. Available from: www.openepi.com.
  11. Esteves SC, Roque M, Bedoschi GM, Conforti A, Humaidan P, Alviggi C. Defining low prognosis patients undergoing assisted reproductive technology: POSEIDON criteria: the why. Front Endocrinol (Lausanne) 2018;9:461.
  12. Nagels HE, Rishworth JR, Siristatidis CS, Kroon B. Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction. Cochrane Database Syst Rev 2015;2015:CD009749.
  13. Gleicher N, Weghofer A, Barad DH. The role of androgens in follicle maturation and ovulation induction: friend or foe of infertility treatment? Reprod Biol Endocrinol 2011;9:116.
  14. Prizant H, Gleicher N, Sen A. Androgen actions in the ovary: balance is key. J Endocrinol 2014;222:R141-51.
  15. Andreeva P, Oprova I, Valkova L, Chaveeva P, Dimova I, Shterev A. The benefits of testosterone therapy in poor ovarian responders undergoing in vitro fertilisation (IVF). EMJ 2020;5:71-9.
  16. Noventa M, Vitagliano A, Andrisani A, Blaganje M, Vigano P, Papaelo E, et al. Testosterone therapy for women with poor ovarian response undergoing IVF: a meta-analysis of randomized controlled trials. J Assist Reprod Genet 2019;36:673-83.
  17. Nielsen ME, Rasmussen IA, Kristensen SG, Christensen ST, Mollgard K, Wreford Andersen E, et al. In human granulosa cells from small antral follicles, androgen receptor mRNA and androgen levels in follicular fluid correlate with FSH receptor mRNA. Mol Hum Reprod 2011;17:63-70.
  18. Jindal PC, Singh MJ. How testosterone therapy is advantageous in improving the art outcome in poor ovarian responders undergoing IVF-ICSI cycles. Fertil Steril 2021;116:e367-8.